Predicting Response to Neoadjuvant Chemotherapy in Bladder Cancer
- 1 July 2020
- journal article
- review article
- Published by Elsevier in European Urology Focus
- Vol. 6 (4) , 642-649
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- FDG-Positron Emission Tomography/Computerized Tomography for Monitoring the Response of Pelvic Lymph Node Metastasis to Neoadjuvant Chemotherapy for Bladder CancerJournal of Urology, 2013
- Molecular mechanisms of cisplatin resistanceOncogene, 2011
- Phase III Study of Molecularly Targeted Adjuvant Therapy in Locally Advanced Urothelial Cancer of the Bladder Based on p53 StatusJournal of Clinical Oncology, 2011
- Predicting response of bladder cancers to gemcitabine and carboplatin neoadjuvant chemotherapy through genome-wide gene expression profilingExperimental and Therapeutic Medicine, 2010
- BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancerAnnals of Oncology, 2010
- Validation study of the prediction system for clinical response of M‐VAC neoadjuvant chemotherapyCancer Science, 2006
- Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatmentAnnals of Oncology, 2006
- Evaluation of Chemotherapy with Magnetic Resonance Imaging in Patients with Regionally Metastatic or Unresectable Bladder CancerEuropean Urology, 2006
- Predicting Response to Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Neoadjuvant Chemotherapy for Bladder Cancers through Genome-Wide Gene Expression ProfilingClinical Cancer Research, 2005
- Absence of p53 Overexpression and Favorable Response to Cisplatin‐based Neoadjuvant Chemotherapy in Urothelial CarcinomasJapanese Journal of Cancer Research, 1998